PSDV pSivida Corp. featured news, full reports, and detailed charts
pSivida Corp. (PSDV) Wrap Up:
pSivida Limited is an Australian company existing pursuant to the Australian Corporations Act 2001 with shares listed on the Australian Stock Exchange, the NASDAQ Global Market, the Frankfurt Stock Exchange and London’s OFEX International Market Service. Our corporate headquarters are located at Level 12 BGC Centre, 28 The Esplanade, Perth WA 6000, Australia, and our phone number is (+61 8) 9226 5099. We also operate subsidiaries in the United Kingdom, Australia and the United States. The legal entity that became pSivida was incorporated as the Sumich Group Ltd in April 1987. The Sumich Group operated a business that was placed into administration or receivership in 1998. pSivida was subsequently formed on December 1, 2000 upon entering into a court-approved arrangement with Sumich Group’s creditors which fully extinguished all prior liabilities as of that time. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f10%2f01%2f0001193125-07-211073.html#FIS_COMPANY_INFORMATION"www.psivida.com
22 Employees
Founded in 1987
pSivida Corp. (PSDV:NASDAQ)
LAST $4.09 USD
CHANGE TODAY +0.08 2.00%
VOLUME 139.5K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of pSivida Corp. (PSDV)
|
OPEN
$3.99
|
PREVIOUS CLOSE
$4.01
|
|
|
DAY HIGH
$4.21
|
DAY LOW
$3.85
|
|
|
52 WEEK HIGH
09/21/09 - $6.25
|
52 WEEK LOW
03/6/09 - $0.60
|
|
|
MARKET CAP
74.8M
|
AVERAGE VOLUME 3 mo
52.5K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
18.3M
|
|
|
PSDV Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
PSDV: Initiated - JAGNote by Ladenburg, Thalmann & Co. Inc.
JAG Media - 11/18/2009 8:47 AM ET
PSDV Top Compensated Officers
Dr. Paul Ashton B.Sc., Ph.D.
Chief Executive Officer, President, Executive...
Age: 48
Total Annual Compensation: $495.0K
Mr. Leonard S. Ross
Principal Financial Officer, Principal Accoun...
Age: 59
Total Annual Compensation: $197.4K
Ms. Lori H. Freedman Esq., B.A., J.D.
Vice President of Corporate Affairs, Secretar...
Age: 43
Total Annual Compensation: $372.0K
Prof. Leigh T. Canham
Chief Scientific Officer, Chief Scientific Of...
Total Annual Compensation: A$207.7K
Dr. Mark Parry-Billings Ph.D.
Research and Development Director of UK pSiMe...
Total Annual Compensation: A$239.7K
Executives, Board Directors
Compensation as of Fiscal Year 2009.
Key developments for pSivida Corp. (PSDV)
pSivida Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2009
11/12/2009
pSivida Corp. reported unaudited consolidated earnings results for the first quarter ended September 30, 2009. For the quarter, the company reported, net loss of $1,591,000 or $0.09 per basic and diluted share compared to net loss of $471,000, or $0.03 per basic and diluted share for the quarter ended September 30, 2008. Total revenues were $3,383,000 against $2,806,000 in the same period of last year. Loss from operations was $107,000 against $2,379,000 in the same period of last year. Loss before income taxes was $1,615,000 against $956,000 in the same period of last year.
pSivida Corp., Q1 2010 Earnings Call, Nov-12-2009
11/5/2009
pSivida Corp., Q1 2010 Earnings Call, Nov 12 2009
pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer
10/21/2009
pSivida Corp. announced the completion of a second pancreatic clinical trial of BrachySil(TM) (P32 BioSilicon(TM)), a potential new brachytherapy treatment for inoperable pancreatic cancer. Six patients were studied at two centers in the UK (Guy's and St Thomas' NHS Foundation Trust and University Hospital, Birmingham). The study was conducted to determine the safety of escalating radiation doses of the BrachySil(TM) device and to determine an optimum dosing level. Tumor response was also measured as a secondary end point. The study escalated the absorbed targeted radiation dose by four-fold from the previous study to 400 Gy (Gy or Gray is a unit of absorbed radiation dose due to ionizing radiation). No device related serious adverse events were experienced at the elevated levels and independent dosimetry experts have concluded from the data that 400 Gy is the optimum dose. The previous safety study presented last year at the American Society of Clinical Oncology-GI showed that BrachySil(TM) in combination with standard chemotherapy (gemcitabine), was well tolerated with no clinically significant adverse events related to the device. Data in the first study showed disease control in 82% of patients. BrachySil(TM) is implanted directly into the tumor and was found to be easily deliverable by endoscopic ultrasound. BrachySil(TM) is a novel oncology product which comprises a combination of BioSilicon(TM) (a proprietary porous silicon) and the isotope 32Phosphorus, a proven anti-cancer therapeutic. It is hoped this product will provide oncologists with an effective and user-friendly new treatment for this disease which has a high unmet clinical need.
PSDV Competitors
| Company | Last | Change |
| Biosensors International Group Ltd | $0.72 SGD | 0.00 |
| Durect Corp | $2.09 USD | -0.02 |
| Hydromer Inc | $0.74 USD | -0.16 |
| QLT Inc | C$3.91 CAD | -0.04 |
| SurModics Inc | $22.92 USD | +0.14 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | PSDV | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.9x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 5.4x |
|
|
PSDV |
||
|
PSDV transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About pSivida Corp.
More news for PSDV
pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien® Study
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp (NASDAQ: PSDV - News)(ASX: PVA - News), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien. Dr. Paul Ashton, CEO of pSivida, said: “We are encouraged with the results we see from this small, 37-patient PK study, particularly as it relates to the safety profile. The lower incidence of elevated IOP with Iluvien in the PK study compared to the higher incidence shown in the data for studies of Retisert® (one of our FDA-approved, surgically inserted products which uses the same steroid), is very promising. In this PK study, we see an increase in efficacy in the high dose group and a decrease in efficacy in the low dose group in the results at 18 months as compared to 12 months. While the efficacy data is encou...Click here to read the whole Article (external link)
pSivida Announces Last Patient in Phase III Iluvien® Trial Completes 2 Year Follow-Up Visit
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit. The Phase III studies compare two doses of Iluvien with sham treatment. “We are very pleased that this important milestone has been achieved and we expect to see top-line 24-month data from the trial in mid-December. Assuming positive data, Alimera expects to file the NDA (New Drug Application) with the FDA in the second quarter of 2010,†said Dr. Paul Ashton, CEO of pSivida.Iluvien is an investigative, extended release intravitreal insert currently under development for the treatment of Diabetic Macular Edema (DME). Each Iluvien insert is designed to provide a sustained therapeutic effec...Click here to read the whole Article (external link)
PSIVIDA CORP. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
pSivida Announces Completion of BrachySil Dose Ranging Study in Pancreatic Cancer
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News)(FF:PV3), a leading drug delivery company today announced the completion of a second pancreatic clinical trial of BrachySil™ (P32 BioSilicon™), a potential new brachytherapy treatment for inoperable pancreatic cancer. Six patients were studied at two centers in the UK (Guy’s and St Thomas’ NHS Foundation Trust and University Hospital, Birmingham). The study was conducted to determine the safety of escalating radiation doses of the BrachySil™ device and to determine an optimum dosing level. Tumor response was also measured as a secondary end point. The study escalated the absorbed targeted radiation dose by four-fold from the previous study to 400 Gy (Gy or Gray is a unit of absorbed radiation dose due to ionizing radiation). No device related serious adverse events were experienced at the elevated levels and independent dosimetry experts have concluded from the data that 400 Gy is the optimum dose.The previous safety study presented last year at the American Society of Clinical Oncology-GI s...Click here to read the whole Article (external link)
pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News)(FWB:PV3), a leading drug delivery company, today announced that its financial results for the first quarter of fiscal year 2010 will be released after market close on Thursday, November 12, 2009, followed the same day by a conference call and live webcast to discuss those results and its business scheduled for 4:30 p.m. ET. The conference call may be accessed by dialing (888) 713-4215 from the U.S. and Canada, or (617) 213-4867 from international locations, passcode 39793756. Interested parties may pre-register to participate at www.theconferencingservice.com/prereg, registration key PUQ43KATB.A replay of the call will be available approximately two ...Click here to read the whole Article (external link)
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009
     PSIVIDA CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands except per share amounts)   Three Months Ended September 30,  2009 2008  Revenues: Collaborative research and development ...Click here to read the whole Article (external link)
Q1 2010 PSIVIDA CORP Earnings Release - After Market Close
Earnings Announcements for Thursday, November 12CompanySymbolTimeConferenceCall3i Group plcIII.LBefore Market Open3SBIO INCSSRXAfter Market CloseListenA.D.A.M., Inc.ADAMTime Not SuppliedListenA2A SpAA2A.MITime Not SuppliedAcciona, S.A.ACXIF.PKBefore Market OpenACSM S P AACS.MITime Not SuppliedADDUS HOMECARE CORPADUSBefore Market OpenListenAdvanSource Biomaterials CorporationASBTime Not SuppliedADVANTAGE OIL & GAS LTDAAVAfter Market CloseAECOMACMBefore Market OpenListenAEFFE SPAAEF.MITime Not SuppliedAEGON N.V.AEGOF.PK01:30 am ETAFC Enterprises, Inc.AFCEAfter Market CloseListenAG GROWTH INTL INCAFN.TOBefore Market OpenAir Transport Services Group, Inc.ATSGTime Not SuppliedListenAldila, Inc.ALDAAfter Market CloseALEO SOLAR AG...Click here to read the whole Article (external link)
PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Note Regarding Forward-Looking Statements Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. All statements other than statements of historical fact are forward-looking statements, including, without limitation, any expectations of revenue, expenses, cash flows, earnings or losses from operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning product research, development and commercialization timelines; any statements of expectations or belief; and any statements of assumptions underlying any of the foregoing. We often, although not always, identify forward-looking statements by using words or phrases such as "likely", "expect", "intend", "anticipate", "believe", "estimate", "plan", "project", "forecast" and "outlook". The following are some of the factors that could cause actual results to differ materially from the forward-looking statements: maintaining key collaboration agreements with Alimera and Pfizer; modification of existing terms of key collaboration agreements with Alimera and Pfizer; uncertainties regarding the achievement of milestones and other contingent contractual payment events; failure to prove safety and efficacy of...Click here to read the whole Article (external link)
PSIVIDA CORP Earnings Call scheduled for 4:30 pm ET today
Call DetailsPSIVIDA CORP Earnings Conference Call (Q1 2010)Thu, Nov 12, 2009, 4:30 pm EasternAbout PSIVIDA CORP (NasdaqGM:PSDV)pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The company’s products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is based in Watertown, Massachusetts.More Info:Quote |Profile |Reports |Msgs |Insider | Financials...Click here to read the whole Article (external link)
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Show all filings for PSIVIDA CORP. | Request a Trial to NEW EDGAR Online Pro Form 8-K for PSIVIDA CORP. 12-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as...Click here to read the whole Article (external link)
Would you like to leave a comment about pSivida Corp. PSDV
Find out what social network information about pSivida Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides pSivida Corp. there is more great information available at Realpennies.com